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ABSTRACT
Anti-angiogenic therapies are an important class of anti-cancer treatment drugs. However, their efficacy
is limited to certain tumors and would benefit from identifying a biomarker predictive of therapeutic
response. TP53 (tumor protein p53) is a tumor suppressor gene frequently mutated in cancer and
implicated in cell-cycle regulation, apoptosis, and angiogenesis. Data from 7,525 unique tumor samples
(representing 30 tumor cohorts) were retrieved from the TCGA database to analyze the relationship
between TP53-mutation status and VEGFA (vascular endothelial growth factor A) expression. Univariate
analyses were done using a Mann-Whitney univariate test or Fisher’s exact test. Parameters with
a p-value (p)≤0.1 in univariate analysis were selected for follow-up multivariate analyses, including TP53-
mutation status, cancer cohorts, cancer subtypes, and VEGFA expression. Our analysis demonstrates
statistically significant increases in VEGFA mRNA tissue expression in TP53-mutated adenocarcinomas
(but not in squamous cancers) compared to TP53 wild-type tumors. This association holds true in
multivariate analyses and remains independent of HIF-1α and MDM2 overexpression. Our findings
provide additional evidence that TP53 mutations are linked to the VEGF pathway, potentially offering
insight into the mechanism behind increased sensitivity to anti-angiogenic therapies observed in some
TP53-mutant tumors.
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Introduction
Personalizing therapy for cancer patients by pairing their
tumor molecular profiles with “matched” treatments has
demonstrated success in several clinical contexts.1–3
However, continuing to identify biomarkers that predict ther-
apeutic response is necessary to expand this approach. In
particular, anti-angiogenic therapies (dugs which target the
neo-vascularization process allowing tumors to self-sustain)
would benefit from identification of a specific biomarker. This
pharmacology class encompasses over ten approved antibo-
dies or small molecule inhibitors that target the vascular
endothelial growth factor/vascular endothelial growth factor
receptor (VEGF/VEGFR) axis (Supplementary Figure S1).
Indeed, one of the best-selling drugs in oncology is bevacizu-
mab, a VEGF-A monoclonal antibody. Though indicated for
use in a variety of cancers, such as renal cancer, colon cancer,
non-small cell lung cancer (NSCLC) and glioblastoma, the
impact on survival in non-selected patients is modest, and
bevacizumab’s approval in metastatic breast cancer was
revoked in 2011 by the Food and Drug Administration
(FDA).4 Anti-angiogenic therapies are also expensive and
have numerous side effects, including gastrointestinal perfora-
tion, hypertension, and hemorrhage.5,6 Identifying specific
parameters that predict response to anti-angiogenesis therapy
may be used to separate patients likely to benefit from those
that might be transferred to an alternative therapy.
TP53 (tumor protein p53) is a multifunctional tumor sup-
pressor gene that is also intimately involved in the process of
neo-vascularization, often through various inhibitory
mechanisms.7 For example, TP53 promotes degradation of
the hypoxia-induced factor subunit α (HIF-1α) in the cell.
HIF-1 serves as a key transcriptional activator of VEGF-
mediated angiogenesis in response to oxygen deprivation.8
The relationship between TP53 and HIF-1α is not yet fully
clear, but TP53 appears to also affect angiogenesis via other
pathways. One study demonstrated that TP53 inhibits VEGF
expression through a pathway involving tumor protein 21
(p21) and retinoblastoma (Rb) in vitro.9 Another study char-
acterized the E2F transcription factor 1 (E2F1) and found an
apparent relationship with TP53 to directly downregulate
VEGF expression in a HIF-1α independent fashion.10 A role
for TP53 in angiogenesis has been established in multiple
studies – in bone marrow stromal cells, transfection of mutant
TP53 increased synthesis of VEGF and supported leukemia
cell growth.11 Angiogenesis is an area of interest in these
disorders, as vascular development has been observed in
lymph nodes and bone marrow in patients with various
hematologic malignancies; treatment strategies are being
explored in this area.12 In a separate study demonstrating
the reverse, the restoration of TP53 expression in
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a population of previously altered-TP53 cells was associated
with decreased angiogenesis.13
Somatic mutations in the TP53 gene are found in high
rates across multiple cancers, such as colorectal, lung, and
head and neck – even ranging up to over 85% in high-grade
ovarian serous carcinoma.14 Mutations in TP53 are used as
markers of clonality, recurrence and cancer prognosis,15 but
are often considered non-actionable by conventional
therapies.
Recently, several studies have suggested that TP53 muta-
tion status may be predictive of clinical sensitivity to VEGF/
VEGFR inhibitors in certain tumors. A recent analysis showed
that VEGFA transcript expression correlated independently
with TP53 mutational status in patients with adenocarcinoma
(but not squamous) NSCLC.16 Additional studies have
demonstrated statistically significant improvements in clinical
outcomes (such as response rate, progression-free survival,
and overall survival) among TP53-mutant patients treated
with anti-VEGF or anti-VEGFR therapies, compared to
TP53- wild-type populations.17–20 The increased expression
of VEGFA may explain the improved response to VEGF/
VEGFR inhibitors in TP53-mutant populations, but to date,
datasets have only interrogated a relatively small number of
patients. Herein, we present an analysis of TP53 mutation
status and VEGF/VEGFR expression in a large pan-cancer
cohort, using a collection of 7525 tumor samples from The
Cancer Genome Atlas (TCGA).
Results
Somatic TP53 mutations are frequent in human tumors
Of 10,011 samples available through the TCGA database, only
7,525 (30 tumor types) included available data on both TP53
mutation status and VEGF pathway transcript expression
estimates (Table 1). Analyses were performed on the full set
of 7,525 samples (pan-cancer cohort) and/or by individual
tumor types.
TP53 mutations were found in 35% of all samples. The
most mutated cohorts, percentage-wise, were uterine carci-
noma (50/56 samples, 89%), ovarian serous cystadenocarci-
noma (210/245, 86%), and squamous NSCLC (145/178, 81%).
In contrast, uveal melanoma (0/80, 0%), pheochromocytoma
and paraganglioma (1/161, 1%), and thyroid carcinoma (3/
397, 1%) contained the lowest percentage of TP53-mutated
samples.
VEGF pathway biomarkers are differentially expressed
in several subsets of TP53-mutated tumors
Table 2 presents the analysis of mRNA expression levels of
key angiogenesis biomarkers, considering the presence or
absence of a somatic TP53 mutation.
When examining specific cancer cohorts,TP53mutationswere
associatedwith a significant increase ofVEGFAmRNAexpression
levels in breast carcinoma, colon adenocarcinoma, and NSCLC
adenocarcinoma, compared to TP53wild-type tumors (univariate
analysis, breast carcinoma p < .001, colon adenocarcinoma
p = .007, NSCLC adenocarcinoma p = .024 – Table 2). VEGFA
expression remained a factor independently associated with TP53
mutation in breast and colon carcinoma in multivariate analysis
models including other VEGF ligands (VEGFA, VEGFB and
VEGFC) and VEGF receptors (FLT1, KDR and NRP1): p < .001,
odds ratio (OR)[Confidence Interval (CI) 95%] = 2.10 [1.74–2.54]
for breast carcinoma, and p = .005, OR[CI95%] = 1.48 [1.13–1.95]
for colon adenocarcinoma – Supplementary Table S1, Panels
B and C). In contrast, squamous NSCLC tumors demonstrated
amarkedly different biomarker expression profile, with significant
decreases in VEGFC, FLT1, and KDR expression levels (VEGFC
p = .030, FLT1 p = .035, KDR p = .007 – Table 2), as well as no
increase in VEGFA expression (in univariate analysis). However,
uponmultivariate analysis, no change in expression in any of these
factors was observed (Supplementary Table S1, panel E).
Glioblastoma showed no significant change in expression in any
factor associated with TP53 mutations (Table 2 and
Supplementary Table S1, panel F).
Similar results were found when considering the combined
tumor set (pan-cancer analysis): angiogenesis ligands demon-
strated significant increases of expression in TP53-mutated
tumors, compared to their wild-type counterparts (multivari-
ate analysis, VEGFA p < .001, VEGFB p = .007, VEGFC
p = .012 – Table 2). Conversely, angiogenesis receptors
demonstrated significant decreases of expression in TP53-
mutated tumors (multivariate analysis, FLT1 p = .049, KDR
p < .001 – Table 2).
Table 1. Description of the pan-cancer cohort (N = 7,525 samples with known
TP53 status).
Total samples TP53-mutated samples
N N (% of subtype)
All cancer cohorts 7,525 2,670 (35%)
Adrenocortical carcinoma 52 12 (23%)
Bladder Urothelial Carcinoma 388 193 (50%)
Breast Invasive Carcinoma 960 292 (30%)
Cervical Squamous Cell Carcinoma &
Endocervical Adenocarcinoma
190 9 (5%)
Cholangiocarcinoma 35 5 (14%)
Colon Adenocarcinoma 360 227 (63%)
Lymphoid Neoplasm Diffuse Large
B-cell Lymphoma
41 5 (12%)
Glioblastoma Multiforme 136 44 (32%)
Head and Neck Squamous Cell
Carcinoma
488 343 (70%)
Kidney Chromophobe 66 22 (33%)
Kidney Renal Clear Cell Carcinoma 431 9 (2%)
Kidney Renal Papillary Cell Carcinoma 161 5 (3%)
Acute Myeloid Leukemia 160 13 (8%)
Brain Lower Grade Glioma 509 247 (49%)
Liver Hepatocellular Carcinoma 190 60 (32%)
Non-small Cell Lung Adenocarcinoma 487 253 (52%)
Non-small Cell Lung Squamous Cell
Carcinoma
178 145 (81%)
Ovarian Serous Adenocarcinoma 245 210 (86%)
Pancreatic Adenocarcinoma 113 72 (64%)
Pheochromocytoma and
Paraganglioma
161 1 (1%)
Prostate Adenocarcinoma 332 41 (12%)
Rectum Adenocarcinoma 119 88 (74%)
Sarcoma 239 80 (33%)
Melanoma Cutaneous 294 48 (16%)
Uveal 80 0 (0%)
Stomach Adenocarcinoma 269 123 (46%)
Testicular Germ Cell Tumors 147 2 (1%)
Thyroid Carcinoma 397 3 (1%)
Uterine Corpus Endometrial
Carcinoma
241 68 (28%)
Uterine Carcinosarcoma 56 50 (89%)
Abbreviations: N = number.
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TP53mutation status remains independently associated
with VEGFA expression in several multivariate models
To investigate the potential confounding effect of additional
factors on VEGFA expression, we conducted three follow-up
multivariate analyses using VEGFA expression as the depen-
dent variable (i.e. the outcome whose variation is being stu-
died) (Table 3). Each statistical model included TP53
mutation status, with additional criteria such as tumor type
(adenocarcinoma or squamous cell carcinoma), tumor locali-
zation, or mRNA expression of biomarkers related to
hypoxia-mediated angiogenesis – hypoxia-induced factor 1
subunit α (HIF1A) and mouse double-minute 2 (MDM2).21
In each multivariate, TP53mutation status appeared indepen-
dently and significantly associated with an increase in VEGFA
expression (p = .022 OR[CI95%] = 1.26 [1.04–1.54], p = .009
OR[CI95%] = 1.31 [1.07–1.60], p = .009 OR[CI95%] = 1.30
[1.07–1.92] – Table 3). This relationship was preserved even in
the presence of HIF1A andMDM2 overexpression.
Outside ofTP53mutation status, NSCLC squamous status also
demonstrated a relationship with VEGFA expression, albeit
a negative one (p = .030 OR[CI95%] = 0.33 [0.12–0.90], p = .031
OR[CI95%] = 0.33 [0.12–0.90] – Table 3), independent from TP53
mutation status.
Both relationships were preserved when VEGFA expression
was evaluated as a continuous variable instead of
Table 2. Angiogenesis factors associated with TP53 mutations in selected and non-selected cancer cohorts.
Univariate Multivariate**
Non-small cell lung carcinoma Pan-cancer
Breast
carcinoma
Colon
carcinoma Adenocarcinoma
Squamous
carcinoma Glioblastoma Pan-cancer OR [95% CI] P-value
Number of TP53-mutated samples
(N)
292 227 253 145 44 2,670 2,670
LIGANDS VEGFA expression Increased
p < .001
Increased
p = .007
Increased
p = .024
- - Increased
p < .001
1.16
[1.10–1.22]
p < .001
VEGFB expression - - - - - Increased
p < .001
1.07
[1.02–1.28]
p = .007
VEGFC expression - - - Decreased
p = .030
- Increased
p = .038
1.07
[1.01–1.12]
p = .012
RECEPTORS FLT1 [VEGFR1]
expression
- - - Decreased
p = .035
- Decreased
p < .001
0.93
[0.86–1.00]
p = .049
KDR [VEGFR2]
expression
Decreased
p = .003
- - Decreased
p = .007
- Decreased
p < .001
0.86
[0.80–0.93]
p < .001
NRP1 expression* - - - - - Decreased
p < .001
- -
7,525 tumors presenting a TP53 mutation were assessed – tumors with a TP53 mutation were compared to those without a TP53 mutation, within individual cohorts.
All p-values ≤.05 were considered significant (Mann Whitney U Test) and are presented.
*NRP1 is a co-receptor interacting with VEGFR1 and VEGFR2.
**p-values ≤0.1 in univariate were selected for multivariate analysis.
Detailed calculations are given in Supplementary Table S1.
Abbreviations: “-“ = non-significant change; 95% CI = 95% confidence interval; N = number; OR = odds ratio.
Table 3. Analysis of factors associated with VEGFA mRNA expression in the pan-cancer cohort (N = 7,525 samples).
VEGFA expression
(categorical variable)*
VEGFA expression
(continuous variable)
Univariate Multivariate** Univariate Multivariate
OR [95% CI] P-value OR [95% CI] P-value P-value P-value
TP53 mutation 1.26 [1.04–1.54] .022 1.26 [1.04–1.54] .022 <.001 <.001
Adenocarcinoma 0.90 [0.74–1.10] .313 - - .448 -
Squamous 1.06 [0.78–1.44] .690 - - .009 -
TP53 mutation 1.26 [1.04–1.54] .022 1.31 [1.07–1.60] .009 <.001 <.001
Breast carcinoma 0.84 [0.61–1.14] .296 - - .288 -
Colon adenocarcinoma 0.61 [0.35–1.07] .101 - - .185 -
NSCLC adenocarcinoma 1.49 [1.06–2.10] .026 - - .240 -
NSCLC squamous 0.38 [0.14–1.02] .047 0.33 [0.12–0.90] .031 <.001 <.001
Glioblastoma 1.04 [0.50–2.13] .852 - - .074 -
TP53 mutation 1.26 [1.04–1.54] .022 1.30 [1.07–1.59] .009 <.001 <.001
HIF1A overexpression 2.01 [1.37–2.96] .001 2.01 [1.36–2.95] <.001 .044 .002
MDM2 overexpression 1.50 [0.96–2.34] .081 - - .609 -
Breast carcinoma 0.84 [0.61–1.14] .296 - - .288 -
Colon adenocarcinoma 0.61 [0.35–1.07] .101 - - .185 -
NSCLC adenocarcinoma 1.49 [1.06–2.20] .026 - - .240 -
NSCLC squamous 0.38 [0.14–1.02] .047 0.33 [0.12–0.90] .031 <.001 <.001
Glioblastoma 1.04 [0.50–2.13] .852 - - .074 -
* VEGFA, HIF1A, MDM2 over-expression were first considered as categorical variables, defined: yes if Z-score for mRNA expression ≥ 1.645 (i.e. biomarker is
significantly overexpressed, compared to pan-cancer expression levels); no if Z-score for mRNA expression <1.645 (i.e. biomarker is not significantly overexpressed,
compared to pan-cancer expression levels).
** Several multivariate models were built, selecting independent variables with p-value≤0.1 from univariate analysis. These include TP53 mutation status, cancer type
(adenocarcinoma vs squamous), selected cancer cohorts (breast, colon, lung and brain tumors), and HIF1A and MDM2 over-expression.
Abbreviations: “-“ = non-significant change; 95% CI = 95% confidence interval; NSCLC = non-small cell lung cancer; OR = odds rate
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a dichotomized categorical variable (TP53 mutation p < .001;
NSCLC squamous status p < .001 – Table 3).
Relationship between specific TP53 mutation hotspots
and VEGF-A expression
We performed a multi-comparison analysis considering dif-
ferent TP53 mutational hostpots such as variants encompass-
ing codons 175, 220, 245, 248, 273 and all other loci.
The level of VEGFA mRNA expression was not signifi-
cantly different between each of these hotspot mutations
(non-parametric ANOVA – Kruskal-Wallis test, p = .903, all
individual comparisons were non-significant), suggesting that
the association between TP53 mutation and VEGFA expres-
sion is independent of the type of variant presented by the
tumor.
Discussion
We provide evidence that somatic TP53 mutation – one of the
most frequent genomic alterations found in human tumors –
is associated with an increase in expression of VEGFA, the
major ligand of the VEGF/VEGFR pathway and a key reg-
ulator of angiogenesis.22 This association, found in a pan-
cancer analysis and in selected histological subsets, remains
independent from other investigated factors and was pre-
served in a bidirectional fashion (i.e. TP53-mutated samples
are enriched for VEGFA overexpression and VEGFA over-
expressed tumors are more likely to present a TP53 mutation,
when considering different confounder variables) (Tables 2
and 3). As VEGF-A and its downstream receptors – FLT1
(VEGFR1) and KDR (VEGFR2) – are the targets of multiple
FDA-approved therapies, demonstrating a relationship
between TP53 mutation and VEGFA expression may help to
explain the correlation between TP53 mutations and favorable
outcomes observed in clinical studies of patients treated with
anti-angiogenesis agents.17–19 Though previously published
data on the predictive value of circulating VEGF-A did not
show a correlation with patient outcome after bevacizumab
treatment, it is also known that blood-derived VEGF-A levels
do not correlate well with tissue VEGF-A expression.23,24
Interestingly, the relationship between VEGF-A expression
and mutant TP53 was found in adenocarcinomas, but not in
squamous cell cancers (Supplementary Table S2 and Table 1).
This distinction has been previously described in NSCLC.16 In
this study, the association between TP53 mutation and
VEGFA expression was established in breast, colon and lung
adenocarcinoma, but not in glioblastoma. Furthermore, lung
squamous cell carcinomas did not present upregulation of
VEGF-A and actually demonstrated downregulation of both
receptors VEGFR1 and VEGFR2 (Table 2). VEGFR2 was
downregulated across squamous cell cancers regardless of
their origin (Supplementary Table S2).
TP53 mutation is a common molecular alteration (35% of all
cancers in our study – Table 1) and is found across diverse
malignancies, with particularly high mutation rates observed in
certain tumor types. High-grade serous ovarian cancers, over 85%
of which harborTP53mutations, are unusual in that they respond
positively to bevacizumab monotherapy.25 Anti-angiogenic
therapies are also important in fields of medicine outside of
oncology. For instance, bevacizumab is effective in the treatment
and prevention of recurrent pterygium, a benign vascular growth
of the eye. Of interest, both TP53mutations and overexpression of
VEGF ligands have been observed in this condition.26–28
Additionally, several pre-clinical studies have shown mechanistic
associations between TP53 mutations and angiogenesis – in the
presence of TP53 mutations, HIF-1α, which is a transcriptional
activator of VEGF-A, is increased.8 Furthermore, transfected
mutant TP53 increases VEGF-A levels in bone marrow stromal
cells.11 In regard to HIF-1α, however, our observations suggested
that VEGF-A and HIF-1α transcripts are both overexpressed in
TP53 mutated tumors, but the higher levels are independently
associated with the TP53 mutations (Table 3). The regulation of
HIF-1α is mostly at the protein level; however, we did not find
a significant association between the presence of TP53 mutation
and HIF-1a protein signal detection obtained by reverse-phase
protein assay (RPPA) from The Cancer Genome Atlas (TCGA)
(mean of protein expression of HIF-1a [95%CI] = 0.20
[−0.46–0.86] vs 0.49 [0.42–0.56], (TP53 mutated versus not)
p = .317); nor a significant association between VEGFA mRNA
overexpression and HIF-1a protein level (mean of HIF-1a protein
level [95%CI] = 0.38 [0.15–0.61] vs 0.49 [0.41–0.57], (VEGF-A
mRNA high versus low) p = .350).
There are limitations to this study. For instance, this study
focuses on TP53 mutational status and does not assess other
genomic variants. However, a more comprehensive study could
possibly highlight additional molecular biomarkers significantly
associated with elevated VEGF pathway expression and merits
future investigation. Another limitation is that TP53mutation is
being used to predict the expression of another biomarker
(VEGF in this case). VEGFA expression or VEGF pathway
expression could serve as a biomarker itself, but examining
biomarkers based on protein expression (such as by immuno-
histochemistry) has produced variable results at times. Still, this
concept should be explored. Another limitation is that we cannot
know, based on the available data, if the TP53 mutations are
heterozygous or homozygous. In addition, we cannot state for
certain that increased VEGF expression explicitly translates to
increased angiogenesis. Another limitation is that many other
genes in addition to VEGF are involved in angiogenesis and
future studies should address the relationship between this com-
plex network of genes and TP53. Finally, categorization of
tumors into adenocarcinomas and squamous cancers across
multiple sites of origin represents an oversimplification; how-
ever, this represents an attempt to further stratify the analyses
completed. Significant further investigation is required to truly
elucidate if increased VEGFAmRNA expression in p53-mutated
tumors is preserved across multiple types of adenocarcinomas.
Based on this data and the above limitations, it cannot be
assumed that all TP53-mutant cancers will respond to anti-
angiogenesis agents or that TP53 wild-type tumors will not
respond; rather the response rates are expected to be higher in
TP53-mutant tumors, consistent with prior studies in the
literature.17–19
In summary, using a large pan-cancer cohort of 7,525
samples, we demonstrate that increased VEGF-A transcript
levels correlate independently with tumor TP53 mutation
status, particularly in adenocarcinomas, independent of their
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organ of origin. This observation may provide a further
mechanistic underpinning for the association between TP53
mutations and response to anti-angiogenesis agents and may
be of great interest when one considers the high frequency of
deleterious TP53 genomic events in human tumors.
Materials and methods
Molecular data retrieval: Data corresponding to 7,525 unique
tumor samples, representing 30 different tumor cohorts, were
retrieved from the TCGA database (https://cancergenome.nih.
gov/): sequencing-based TP53 mutation status and mRNA
expression Z-scores (indicating the number of standard devia-
tions away from the mean expression level of the population)
of angiogenesis ligands VEGFA, VEGFB, and VEGFC; recep-
tors FMS-like Tyrosine Kinase-1 (FLT1 or VEGFR1) and
Kinase Insert Domain Receptor (KDR or VEGFR2); and co-
receptor Neuropilin-1 (NRP1, co-receptor to FLT1 and KDR)
(Supplementary Figure S1).
TP53 mutation and VEGF biomarker expression associa-
tion analyses: We analyzed the association between TP53
mutation status and mRNA expression levels of the genes
listed above. This analysis was carried out for the entire
tumor set as well as for common cancer cohorts in which
bevacizumab is commonly used – glioblastoma, NSCLC, and
colon cancer. Breast cancer was also included due to the
availability of a large number of samples and because bevaci-
zumab was formerly indicated for this disease. We further
analyzed the relative associations between factors such as
TP53-mutation status, cancer cohorts, cancer subtypes, and
VEGFA expression (multivariate analysis). VEGFA expression
was characterized as a continuous variable and also dichoto-
mized as a categorical variable, defining mRNA expression
Z-scores ≥1.645 as “overexpression” of VEGFA. A Z-score
≥1.645 corresponds to a value in the top 5% of biomarker
expression, conferring significance considering a one-tailed
p-value of 0.05.
Statistical analysis: Statistical analyses were performed by
AB, using SAS University Edition. All univariate analyses
were done using a Mann-Whitney univariate test or Fisher’s
exact test. Parameters with a p-value (p)≤0.1 in univariate
analysis were selected for follow-up multivariate analyses, in
order to further describe the factors independently associated
with TP53 mutation or VEGFA overexpression. P-values
≤0.05 were considered statistically significant.
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